Ignite Creation Date:
2024-05-06 @ 3:20 AM
Last Modification Date:
2024-10-26 @ 11:32 AM
Study NCT ID:
NCT02269215
Status:
COMPLETED
Last Update Posted:
2014-10-21
First Post:
2014-10-20
Brief Title:
Single Increasing Doses of BIII 890 CL in Healthy Young Male Volunteers and in Healthy Elderly Male and Female Volunteers
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
A Single Blind Placebo-controlled Parallel-group Single Increasing Dose Tolerance Study in Healthy Young Male Volunteers After Intravenous Administration of BIII 890 CL as Loading Dose Dosage 125 25 50 mgh Infusion Time 1 hr 50 mgh Infusion Time 2 Hrs Followed by Maintenance Dose Dosage 625 125 25 mgh Infusion Time 5 Hrs 30 mgh Infusion Time 4 Hrs and in Healthy Elderly Male and Female Volunteers After Intravenous Administration of BIII 890 CL as Loading Dose Dosage 50 mgh Infusion Time 1 hr Followed by Maintenance Dose Dosage 25 mgh Infusion Time 5 Hrs
Status:
COMPLETED
Status Verified Date:
2014-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Safety tolerability and pharmacokinetics of BIII 890
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None